Recent News

• 12.15.2025 - TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
• 12.11.2025 - TuHURA Biosciences Provides Corporate Update Following Recent Financing
• 12.09.2025 - TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
• 12.08.2025 - TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
• 11.14.2025 - TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
• 11.03.2025 - TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

Recent Filings

• 12.10.2025 - 8-K Current report
• 12.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.10.2025 - EX-99.1 EX-99.1
• 12.05.2025 - 8-K Current report
• 11.25.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.25.2025 - 8-K Current report
• 11.18.2025 - 8-K Current report
• 11.18.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 8-K Current report
• 11.14.2025 - EX-99.1 EX-99.1